Streetbeat News

Products Services

RNAC

The FDA has granted Rare Pediatric Disease Designation to Cartesian Therapeutics' Descartes-08 for the treatment of Juvenile Dermatomyositis, a rare inflammatory disease. This designation could potentially expedite the development and review process for Descartes-08.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:12 am

TNXP

Tonix Pharmaceuticals presented promising data on its potential Mpox vaccine, TNX-801, at an immunology symposium. The vaccine showed efficacy in protecting animals and improved tolerability in immunocompromised subjects. It has been selected by NIH's Project NextGen for clinical testing.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:11 am

ACB

Aurora Cannabis Inc. has launched a new CBD lozenge in Canada, developed in collaboration with Vectura Fertin Pharma. The product is available through Aurora's e-commerce platform, marking Vectura's first medical cannabis product in Canada.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:08 am

TERN

Terns Pharmaceuticals reported positive topline data from its Phase 1 trial of TERN-601, showing a statistically significant mean weight loss of up to 5.5% over 28 days in healthy adults with obesity or overweight.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:07 am

IMVT

ROIV

Immunovant reported positive Phase 2a trial results for Batoclimab in Graves' Disease, showing a 76% response rate in patients uncontrolled on antithyroid drugs. The company plans to start a pivotal trial for IMVT-1402 by the end of 2024, with FDA alignment and IND clearance.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:06 am

EVAX

Evaxion Biotech has announced promising pre-clinical results for its mRNA-based gonorrhea vaccine, EVX-B2, demonstrating its ability to eliminate gonorrhea bacteria. This data will be presented at the 18th Vaccine Congress in Lisbon.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:03 am

AKRO

Akero Therapeutics has initiated the Phase 3 Synchrony Outcomes trial by dosing the first patient. This study will assess the efficacy and safety of Efx for treating compensated cirrhosis, fibrosis stage 4, due to metabolic dysfunction-associated steatohepatitis.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:03 am

AMIX

Autonomix Medical, Inc. (NASDAQ:AMIX) announced positive preliminary results from its clinical trial on nerve ablation for pancreatic cancer pain, showing potential in pain mitigation.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:02 am

AAPL

BA

DELL

NVDA

ORCL

PLTR

QQQ

SPY

U.S. stocks are poised for a rebound, driven by tech stocks and Apple's Glowtime event, despite recent market declines due to weak economic data. Key events include inflation reports and a presidential debate. Notable stock movements include Palantir and Dell's inclusion in the S&P 500, and Boeing's labor agreement.

Portfolio Pulse from Shanthi Rexaline

September 09, 2024 | 11:01 am

BP

PLTR

Palantir and BP are extending their strategic relationship by introducing new AI capabilities using Palantir's AIP software. This software will help BP utilize large language models to enhance decision-making processes.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:00 am